The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A Review of Neuroprotection Pharmacology and Therapies in Patients with Acute Traumatic Brain Injury
Abstract
Traumatic brain injury (TBI) affects 1.6 million Americans annually. The injury severity impacts the overall outcome and likelihood for survival. Current treatment of acute TBI includes surgical intervention and supportive care therapies. Treatment of elevated intracranial pressure and optimizing cerebral perfusion are cornerstones of current therapy. These approaches do not directly address the secondary neurological sequelae that lead to continued brain injury after TBI. Depending on injury severity, a complex cascade of processes are activated and generate continued endogenous changes affecting cellular systems and overall outcome from the initial insult to the brain. Homeostatic cellular processes governing calcium influx, mitochondrial function, membrane stability, redox balance, blood flow and cytoskeletal structure often become dysfunctional after TBI. Interruption of this cascade has been the target of numerous pharmacotherapeutic agents investigated over the last two decades. Many agents such as selfotel, pegorgotein (PEG-SOD), magnesium, deltibant and dexanabinol were ineffective in clinical trials. While progesterone and ciclosporin have shown promise in phase II studies, success in larger phase III, randomized, multicentre, clinical trials is pending. Consequently, no neuroprotective treatment options currently exist that improve neurological outcome after TBI. Investigations to date have extended understanding of the injury mechanisms and sites for intervention.…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, no effective interventions are available to improve recovery following TBI (42–44).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [42]
Citations
Cites
A controlled cortical impact model of traumatic brain injury in the rat
Edward Dixon, C., Clifton, G. L., Lighthall, J. W., Yaghmai, A. A., & Hayes, R. L. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90104-8 · Cited by 1,141
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913
Antioxidant Therapies for Traumatic Brain Injury
Hall, E. D., Vaishnav, R. A., & Mustafa, A. G. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2009.10.021 · Cited by 390 · cited 1×
“These reactive species may overwhelm endogenous antioxidant stores, such as superoxide dismutase (SOD), causing DNA damage and lipid peroxidation, which can propagate well beyond the site of origin.([38,39]) The inflammatory response to TBI, like inmany other types of critical illness, can either be harmful or helpful…”
BackgroundÅberg, N. D., Brywe, K. G., & Isgaard, J. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.22 · Cited by 387
Experimental models of traumatic brain injury: do we really need to build a better mousetrap?
Morales, D. M., Marklund, N., Lebold, D., Thompson, H. J., Pitkanen, A., Maxwell, W. L., Longhi, L., Laurer, H., Maegele, M., Neugebauer, E., et al. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.030 · Cited by 339 · cited 1×
“However, the heterogeneity of TBI in reality is difficult to replicate.([71]) Patients often present with more than one abnormality or injury type due to neurotrauma.”
BackgroundOertel, M., Boscardin, W. J., Obrist, W. D., Glenn, T. C., McArthur, D. L., Gravori, T., Lee, J. H., & Martin, N. A. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.103.5.0812 · Cited by 227
Ropper, A. H., & Gorson, K. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp064645 · Cited by 215
Saatman, K. E., Contreras, P. C., Smith, D. H., Raghupathi, R., McDermott, K. L., Fernandez, S. C., Sanderson, K. L., Voddi, M., & McIntosh, T. K. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6629 · Cited by 185
Research works printed but not linked: 203
- Thurman, 1999 Sep 8, JAMA, 282, 954, 10.1001/jama.282.10.954 · DOI
- Thurman, 1999 Dec, J Head Trauma Rehabil, 14, 602, 10.1097/00001199-199912000-00009 · DOI
- Coronado, 2011 May 6, MMWR Surveill Summ, 60, 1
- Roozenbeek, 2012, J Neurotrauma, 29, 1306, 10.1089/neu.2011.1988 · DOI
- Clifton, 2011 Feb, Lancet Neurol, 10, 131, 10.1016/S1474-4422(10)70300-8 · DOI
- Patel, 2005 Oct 29-Nov 4, Lancet, 366, 1538, 10.1016/S0140-6736(05)67626-X · DOI
- Marshall, 1991, J Neurosurg, 75, S28, 10.3171/sup.1991.75.1s.0s28 · DOI
- Roberts, 2004 Oct 9-15, Lancet, 364, 1321, 10.1016/S0140-6736(04)17188-2 · DOI · Paper page
- De Kruijk, 2002 Dec, J Neurol Neurosurg Psychiatr, 73, 727, 10.1136/jnnp.73.6.727 · DOI
- Ryan, 2003 Nov, Int Rev Psychiatry, 15, 310, 10.1080/09540260310001606692 · DOI
- Ling, 2009 Jun, J Neurotrauma, 26, 815, 10.1089/neu.2007.0484 · DOI
- Sahuquillo, 2001, Curr Pharm Des, 7, 1475, 10.2174/1381612013397311 · DOI
- Andriessen, 2010 Oct, J Cell Mol Med, 14, 2381, 10.1111/j.1582-4934.2010.01164.x · DOI
- 2007, J Neurotrauma, 24, S1, 10.1089/neu.2007.9997 · DOI
- Rhoney, 2006, Nutr Clin Pract, 21, 462, 10.1177/0115426506021005462 · DOI
- Clifton, 2002, Crit Care Med, 30, 739, 10.1097/00003246-200204000-00003 · DOI
- Hatton, 2001, CNS Drugs, 15, 553, 10.2165/00023210-200115070-00005 · DOI
- Werner, 2007 Jul, Br J Anaesth, 99, 4, 10.1093/bja/aem131 · DOI · Paper page
- Enriquez, 2004, Curr Pharm Des, 10, 2131, 10.2174/1381612043384060 · DOI
- Czosnyka, 2001 Nov, J Neurosurg, 95, 756, 10.3171/jns.2001.95.5.0756 · DOI
- Manley, 2001 Oct, Arch Surg, 136, 1118, 10.1001/archsurg.136.10.1118 · DOI
- DeWitt, 2003 Sep, J Neurotrauma, 20, 795, 10.1089/089771503322385755 · DOI · Paper page
- Steiner, 2003 Oct, Stroke, 34, 2404, 10.1161/01.STR.0000089014.59668.04 · DOI
- Cherian, 2004 Apr, Brain Pathol, 14, 195, 10.1111/j.1750-3639.2004.tb00053.x · DOI
- Schroder, 1998, Acta Neurochir Suppl, 71, 127
- Schroder, 1996 Jan, J Neurotrauma, 13, 17, 10.1089/neu.1996.13.17 · DOI
- Obrist, 1984 Aug, J Neurosurg, 61, 241, 10.3171/jns.1984.61.2.0241 · DOI
- Overgaard, 1974 Nov, J Neurosurg, 41, 531, 10.3171/jns.1974.41.5.0531 · DOI
- Martin, 1997 Jul, J Neurosurg, 87, 9, 10.3171/jns.1997.87.1.0009 · DOI
- Langham, 2003, Cochrane Database Syst Rev, 4, CD000565
- Hall, 1993 Feb, J Neurochem, 60, 588, 10.1111/j.1471-4159.1993.tb03189.x · DOI
- Shohami, 1997 Oct, J Cerebral Blood Flow Metab, 17, 1007, 10.1097/00004647-199710000-00002 · DOI
- Lewen, 2000 Oct, J Neurotrauma, 17, 871, 10.1089/neu.2000.17.871 · DOI · Paper page
- Ray, 2002 Oct, Histol Histopathol, 17, 1137
- Lenzlinger, 2001 Aug-Dec, Mol Neurobiol, 24, 169, 10.1385/MN:24:1-3:169 · DOI · Paper page
- Yang, 2007 Sep, Neurosci Bull, 23, 307, 10.1007/s12264-007-0046-6 · DOI
- Ott, 1994, J Neurotrauma, 11, 447, 10.1089/neu.1994.11.447 · DOI
- Royo, 1999 Apr 26, Neuroreport, 10, 1363, 10.1097/00001756-199904260-00038 · DOI
- Stahel, 1998 Aug, Brain Res Brain Res Rev, 27, 243, 10.1016/S0165-0173(98)00015-0 · DOI
- Baldwin, 1996 Sep, J Neurosurg, 85, 476, 10.3171/jns.1996.85.3.0476 · DOI
- Marmarou, 2007, Neurosurg Focus, 22, 1, 10.3171/foc.2007.22.5.2 · DOI
- Venero, 2004, Curr Pharm Des, 10, 2153, 10.2174/1381612043384150 · DOI
- Young, 1992 Mar, J Neurotrauma, 9, S9
- Kawamata, 1995 Mar 20, Brain Res, 674, 196, 10.1016/0006-8993(94)01444-M · DOI
- Mazzeo, 2009 Aug, Exp Neurol, 218, 363, 10.1016/j.expneurol.2009.05.026 · DOI
- Sullivan, 2005, J Neurosci Res, 79, 231, 10.1002/jnr.20292 · DOI
- Kampfl, 1997 Mar, J Neurotrauma, 14, 121, 10.1089/neu.1997.14.121 · DOI
- Raghupathi, 2004 Apr, Brain Pathol, 14, 215, 10.1111/j.1750-3639.2004.tb00056.x · DOI
- Sarnaik, 2010 Mar, J Neurotrauma, 27, 465, 10.1089/neu.2009.1171 · DOI
- Hatton, 2006 Dec, J Neurosurg, 105, 843, 10.3171/jns.2006.105.6.843 · DOI · Paper page
- Neff, 1993 Dec, J Neurobiol, 24, 1578, 10.1002/neu.480241203 · DOI
- Saenger, 2011 Oct, Growth Horm IGF Res, 21, 292, 10.1016/j.ghir.2011.07.006 · DOI
- Taguchi, 2008, Annu Rev Physiol, 70, 191, 10.1146/annurev.physiol.70.113006.100533 · DOI
- Zeger, 2007 Mar, Glia, 55, 400, 10.1002/glia.20469 · DOI
- Kazanis, 2004 Apr, Exp Neurol, 186, 221, 10.1016/j.expneurol.2003.12.004 · DOI
- Rockich, 1999, Pharmacotherapy, 19, 1432, 10.1592/phco.19.18.1432.30891 · DOI
- Metzger, 2011 Jun 3, J Biol Chem, 286, 19501, 10.1074/jbc.M110.172189 · DOI
- Xi, 2002, Neurosurg Clin N Am, 13, 371, 10.1016/S1042-3680(02)00007-4 · DOI
- Schouten, 2007, Curr Opin Crit Care, 13, 134, 10.1097/MCC.0b013e3280895d5c · DOI · Paper page
- Bullock, 1999, Neurosurgery, 45, 207, 10.1097/00006123-199908000-00001 · DOI
- Tolias, 2004, NeuroRx, 1, 71, 10.1602/neurorx.1.1.71 · DOI
- Sullivan, 2000, Neuroscience, 101, 289, 10.1016/S0306-4522(00)00380-8 · DOI
- Lee, 2001, Pharmacol Rev, 53, 569, 10.1146/annurev.pharmtox.41.1.569 · DOI
- Loscher, 2005, Nature Rev Neurosci, 6, 591, 10.1038/nrn1728 · DOI
- Boucher, 1998, Clin Pharmacokinet, 35, 209, 10.2165/00003088-199835030-00004 · DOI
- McKindley, 1997, J Clin Pharmacol, 37, 129, 10.1002/j.1552-4604.1997.tb04771.x · DOI
- Baraldo, 1999, Pharmacol Res, 40, 483, 10.1006/phrs.1999.0539 · DOI
- Kovarik, 1999, Drugs Aging, 15, 197, 10.2165/00002512-199915030-00003 · DOI
- Ptachcinski, 1985, Clin Pharmacol Ther, 38, 296, 10.1038/clpt.1985.174 · DOI
- Cook, 2009, Expert Opin Drug Saf, 8, 411, 10.1517/14740330903066742 · DOI
- Empey, 2006, J Neurotrauma, 23, 109, 10.1089/neu.2006.23.109 · DOI · Paper page
- Temkin, 2007, Lancet Neurol, 6, 29, 10.1016/S1474-4422(06)70630-5 · DOI
- Wright, 2007, Ann Emerg Med, 49, 391, 10.1016/j.annemergmed.2006.07.932 · DOI
- Guilfoyle, 2010 Dec, J Neurotrauma, 27, 2173, 10.1089/neu.2010.1353 · DOI
- von Steinbuchel, 2010 Jul, J Neurotrauma, 27, 1157, 10.1089/neu.2009.1077 · DOI
- Pineda, 2007 Feb, J Neurotrauma, 24, 354, 10.1089/neu.2006.003789 · DOI
- Manley, 2010 Nov, Arch Phys Med Rehabil, 91, 1667, 10.1016/j.apmr.2010.05.018 · DOI
- Ottens, 2010 Oct, J Neurotrauma, 27, 1837, 10.1089/neu.2010.1374 · DOI
- Kochanek, 2008 Apr, Curr Opin Crit Care, 14, 135, 10.1097/MCC.0b013e3282f57564 · DOI
- Maas, 2006, Lancet Neurol, 5, 38, 10.1016/S1474-4422(05)70253-2 · DOI
- Marmarou, 2005 Dec, J Neurotrauma, 22, 1444, 10.1089/neu.2005.22.1444 · DOI
- Hatton, 2008, J Neurosurg, 109, 699, 10.3171/JNS/2008/109/10/0699 · DOI
- Marmarou, 1999 Jun, J Neurotrauma, 16, 431, 10.1089/neu.1999.16.431 · DOI
- Young, 1996 Aug, JAMA, 276, 538, 10.1001/jama.1996.03540070034027 · DOI
- Muizelaar, 1993, J Neurosurg, 78, 375, 10.3171/jns.1993.78.3.0375 · DOI
- Xiao, 2008, Crit Care, 12, R61, 10.1186/cc6887 · DOI
- Merchant, 1999, Ann N Y Acad Sci, 890, 42, 10.1111/j.1749-6632.1999.tb07979.x · DOI
- Yurkewicz, 2005 Dec, J Neurotrauma, 22, 1428, 10.1089/neu.2005.22.1428 · DOI
- Maas, 2006 Jan, Lancet Neurol, 5, 38, 10.1016/S1474-4422(05)70253-2 · DOI
- Natale, 2007, Pediatr Crit Care Med, 8, 1, 10.1097/01.pcc.0000256620.55512.5f · DOI
- Bailey, 1991, Acta Neurochir (Wien), 110, 97, 10.1007/BF01400674 · DOI
- Teasdale, 1992, J Neurotruama, 9, S545
- Murray, 1996, Acta Neurochir (Wien), 138, 1163, 10.1007/BF01809745 · DOI
- 1994, J Neurosurg, 80, 797, 10.3171/jns.1994.80.5.0797 · DOI
- Pillai, 2003, Neurol India, 51, 361
- Zhou, 2002, Di Yi Jun Yi Da Xue Xue Bao, 22, 527
- Tapia-Perez, 2008, J Neurotrauma, 25, 1011, 10.1089/neu.2008.0554 · DOI
- Morris, 1999, J Neurosurg, 91, 737, 10.3171/jns.1999.91.5.0737 · DOI
- Marshall, 1998, J Neurosurg, 89, 519, 10.3171/jns.1998.89.4.0519 · DOI
- LaPlaca, 2001, J Neurotrauma, 18, 369, 10.1089/089771501750170912 · DOI
- Hoane, 2008, Oxid Med Cell Longev, 1, 46, 10.4161/oxim.1.1.6694 · DOI
- Goffus, 2010, Oxid Med Cell Longev, 3, 145, 10.4161/oxim.3.2.11315 · DOI
- Swan, 2011, J Neurotrauma, 28, 431, 10.1089/neu.2010.1519 · DOI
- Hoane, 2006, J Neurotrauma, 23, 1535, 10.1089/neu.2006.23.1535 · DOI
- Holland, 2008, J Neurotruama, 25, 140, 10.1089/neu.2007.0312 · DOI
- Hoane, 2008, Neuroscience, 154, 861, 10.1016/j.neuroscience.2008.04.044 · DOI
- Abdel Baki, 2010, PLoS ONE, 5, e12490, 10.1371/journal.pone.0012490 · DOI
- Chen, 2008, Mediators Inflamm, 2008, 716458, 10.1155/2008/716458 · DOI
- Khan, 2011 July 6, J Neuroinflammation, 8, 78, 10.1186/1742-2094-8-78 · DOI
- Khan, 2009 Nov 4, J Neuroinflammation, 6, 32, 10.1186/1742-2094-6-32 · DOI
- Qu, 2010, J Neurotrauma, 27, 1625, 10.1089/neu.2010.1359 · DOI
- Arun, 2010, J Neurotruama, 27, 293, 10.1089/neu.2009.0994 · DOI
- Appelberg, 2009, J Neurotrauma, 26, 497, 10.1089/neu.2008.0664 · DOI
- Pike, 1995, Brain Res, 686, 37, 10.1016/0006-8993(95)00448-Y · DOI
- Durmaz, 2003 Nov 15, J Neurol Sci, 215, 87, 10.1016/S0022-510X(03)00207-7 · DOI
- Durmaz, 2003 May, Can J Neurol Sci, 30, 143, 10.1017/S0317167100053415 · DOI
- Lu, 2009, J Neurotrauma, 26, 141, 10.1089/neu.2008.0629 · DOI
- Wei, 2009 August 7, J Neuroinflammation, 6, 19, 10.1186/1742-2094-6-19 · DOI
- Berman, 2000, J Neurosurg, 93, 821, 10.3171/jns.2000.93.5.0821 · DOI
- Verweij, 2000, J Neurosurg, 93, 829, 10.3171/jns.2000.93.5.0829 · DOI
- Faden, 2001, Exp Neurol, 167, 435, 10.1006/exnr.2000.7577 · DOI
- Movsesyan, 2001, J Pharmacol Exp Ther, 296, 41
- Barbre, 2006, Brain Res Bull, 69, 639, 10.1016/j.brainresbull.2006.03.009 · DOI
- Hoane, 2005, J Neurotrauma, 22, 1112, 10.1089/neu.2005.22.1112 · DOI
- Belayev, 2002, J Neurosurg, 96, 1077, 10.3171/jns.2002.96.6.1077 · DOI
- Guluma, 1999, J Neurotrauma, 16, 311, 10.1089/neu.1999.16.311 · DOI
- Dietrich, 1996, J Neurotrauma, 13, 309, 10.1089/neu.1996.13.309 · DOI
- McDermott, 1997, J Neurotrauma, 14, 191, 10.1089/neu.1997.14.191 · DOI
- Sun, 2009, Exp Neurol, 216, 56, 10.1016/j.expneurol.2008.11.011 · DOI
- Cernak, 2002, Exp Brain Res, 147, 193, 10.1007/s00221-002-1245-z · DOI
- Wahl, 2000 Nov, J Neurotrauma, 17, 1055, 10.1089/neu.2000.17.1055 · DOI
- Stutzmann, 2002 Spring, CNS Drug Rev, 8, 1, 10.1111/j.1527-3458.2002.tb00213.x · DOI
- Bye, 2007 Mar, Exp Neurol, 204, 220, 10.1016/j.expneurol.2006.10.013 · DOI
- Crack, 2009 Jan, J Neural Transm, 116, 1, 10.1007/s00702-008-0145-1 · DOI
- Homsi, 2009 Sep 29, Brain Res, 1291, 122, 10.1016/j.brainres.2009.07.031 · DOI
- Homsi, 2010 May, J Neurotrauma, 27, 911, 10.1089/neu.2009.1223 · DOI
- Stover, 2000, J Neurotrauma, 17, 1171, 10.1089/neu.2000.17.1171 · DOI
- Zhang, 1998, J Neurosci Res, 52, 342, 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8 · DOI
- Zhang, 2009, Brain Res, 1294, 153, 10.1016/j.brainres.2009.07.077 · DOI
- Zhang, 2010, Brain Res, 1353, 249, 10.1016/j.brainres.2010.07.046 · DOI
- Liao, 2008, Eur J Neurol, 15, 140, 10.1111/j.1468-1331.2007.02013.x · DOI
- Zhao, 2011, Cytokine, 56, 343, 10.1016/j.cyto.2011.07.018 · DOI
- Hartley, 2008, J Neurosurg, 109, 708, 10.3171/JNS/2008/109/10/0708 · DOI
- Grasso, 2007, Brain Res, 1182, 99, 10.1016/j.brainres.2007.08.078 · DOI
- Chen, 2007, Neurosci Lett, 425, 177, 10.1016/j.neulet.2007.08.022 · DOI
- Liao, 2009, Neurol India, 57, 722, 10.4103/0028-3886.59466 · DOI
- Mammis, 2009, Surg Neurol, 71, 527, 10.1016/j.surneu.2008.02.040 · DOI
- Xiong, 2011, J Neurosurg, 114, 549, 10.3171/2010.10.JNS10925 · DOI
- Xiong, 2010, J Neurosurg, 113, 598, 10.3171/2009.9.JNS09844 · DOI
- Brines, 2000, Proc Natl Acad Sci USA, 97, 10526, 10.1073/pnas.97.19.10526 · DOI
- Kuypers, 2010, J Neurotrauma, 27, 1275, 10.1089/neu.2010.1327 · DOI
- Kleindienst, 2004, J Neurotrauma, 21, 541, 10.1089/089771504774129874 · DOI
- Kleindienst, 2005, J Neurotruama, 22, 645, 10.1089/neu.2005.22.645 · DOI
- Kline, 2002, J Neurotrauma, 19, 415, 10.1089/08977150252932370 · DOI
- Mauler, 2003, Brain Res, 989, 99, 10.1016/S0006-8993(03)03376-6 · DOI
- Mauler, 2003, CNS Drug Rev, 9, 343, 10.1111/j.1527-3458.2003.tb00259.x · DOI
- Mesenge, 1996, J Neurotrauma, 13, 11, 10.1089/neu.1996.13.11 · DOI
- Hogg, 1998, Behav Brain Res, 93, 157, 10.1016/S0166-4328(97)00145-9 · DOI
- Bernert, 1996, Proc Natl Acad Sci USA, 93, 5235, 10.1073/pnas.93.11.5235 · DOI
- Ikonomidou, 1996, Metab Brain Dis, 11, 125, 10.1007/BF02069500 · DOI
- Pohl, 1999, Proc Natl Acad Sci USA, 96, 2508, 10.1073/pnas.96.5.2508 · DOI
- McIntosh, 1999, J Neurochem, 55, 1170, 10.1111/j.1471-4159.1990.tb03122.x · DOI
- Okiyama, 1998, Brain Res, 792, 291, 10.1016/S0006-8993(98)00158-9 · DOI
- Kroppenstedt, 1998, J Neurotrauma, 15, 191, 10.1089/neu.1998.15.191 · DOI
- Toulmond, 1993, Brain Res, 620, 32, 10.1016/0006-8993(93)90267-Q · DOI
- Hogg, 1998, J Neurotrauma, 15, 545, 10.1089/neu.1998.15.545 · DOI
- Mueller, 2000, Amino Acids, 19, 177, 10.1007/s007260070047 · DOI
- Dohi, 2006, J Neurotrauma, 23, 1591, 10.1089/neu.2006.23.1591 · DOI
- Itoh, 2010, Neurochem Res, 35, 348, 10.1007/s11064-009-0061-2 · DOI
- Wang, 2011, J Neurotrauma, 28, 2123, 10.1089/neu.2011.1939 · DOI
- Belayev, 2001, J Neurotrauma, 18, 1031, 10.1089/08977150152693728 · DOI
- Kline, 2001, Neuroscience, 106, 547, 10.1016/S0306-4522(01)00300-1 · DOI
- Mauler, 2005, J Cereb Blood Flow Metab, 25, 451, 10.1038/sj.jcbfm.9600038 · DOI
- Cheng, 2007, Neurosci Lett, 416, 165, 10.1016/j.neulet.2007.02.006 · DOI
- Cheng, 2008, Behav Brain Res, 194, 79, 10.1016/j.bbr.2008.06.025 · DOI
- Kline, 2007, Behav Brain Res, 177, 186, 10.1016/j.bbr.2006.11.036 · DOI
- Kline, 2004, J Neurotrauma, 21, 175, 10.1089/089771504322778631 · DOI
- Kline, 2010, J Neurotruama, 27, 2021, 10.1089/neu.2010.1535 · DOI
- Kline, 2002, Neurosci Lett, 333, 179, 10.1016/S0304-3940(02)01101-1 · DOI
- Ma, 2011, Mol Med Rep, 4, 849
- Wallenquist, 2009, Restor Neurol Neurosci, 2009, 323
- Harting, 2009, J Surg Res, 153, 188, 10.1016/j.jss.2008.03.037 · DOI
- Shohami, 1996, J Cereb Blood Flow Metab, 16, 378, 10.1097/00004647-199605000-00004 · DOI
- Chio, 2010, J Neurochem, 115, 921, 10.1111/j.1471-4159.2010.06969.x · DOI
- Kinoshita, 2002, J Neurotrauma, 19, 681, 10.1089/08977150260139075 · DOI
- Liu-DeRyke, 2009, Neurocrit Care, 11, 151, 10.1007/s12028-009-9228-6 · DOI
- Rovlias, 2000, Neurosurgery, 46, 342, 10.1097/00006123-200002000-00015 · DOI
- Salim, 2009, Am Surg, 75, 25, 10.1177/000313480907500105 · DOI
- Diaz-Parejo, 2003, Intensive Care Med, 29, 544, 10.1007/s00134-003-1669-3 · DOI
- Alderson, 2005 Jan 25, Cochrane Database Syst Rev, 1, CD000196
- Mazzeo, 2008, Acta Neurochir (Wien), 150, 1019, 10.1007/s00701-008-0021-7 · DOI
- Mazzeo, 2009 Dec, J Neurotrauma, 26, 2195, 10.1089/neu.2009.1012 · DOI
- Knoller, 2002, Crit Care Med, 30, 548, 10.1097/00003246-200203000-00009 · DOI
- McIntosh, 1988, J Neurotrauma, 5, 17, 10.1089/neu.1988.5.17 · DOI
- Lee, 2004, J Neurotrauma, 21, 549, 10.1089/089771504774129883 · DOI
- Hoane, 2005, Restor Neurol Neurosci, 23, 67
- Wagstaff, 1995 Sep 15, Ann N Y Acad Sci, 15, 332, 10.1111/j.1749-6632.1995.tb16607.x · DOI
- Bullock, 1999, Ann N Y Acad Sci, 51-, 8
- Stein, 2008, Brain Res Rev, 57, 386, 10.1016/j.brainresrev.2007.06.012 · DOI
- Weant, 2007, Pharmacotherapy, 27, 1279, 10.1592/phco.27.9.1279 · DOI
200 of 203 shown
Cited by
Sorted by citations
Items 101–152 of 152
Emerging pharmacological agents to improve survival from traumatic brain injury
Radosevich, J. J., Patanwala, A., & Erstad, B. (2013) · Brain Injury · doi:10.3109/02699052.2013.823658 · Cited by 15
Update on Neuroprotection after Traumatic Brain Injury
Cook, A. M., Michas, M. E., & Robbins, B. T. (2025) · CNS Drugs · doi:10.1007/s40263-025-01173-9 · Cited by 16
“Excitatory neurotransmitters, such as glutamate, are over-abundant, leading to disorganized and aberrant cell discharge and energy consumption [3, 12].”
InfluentialSelf-citationDietary Zinc Modulates Matrix Metalloproteinases in Traumatic Brain Injury
Scrimgeour, A. G., Carrigan, C. T., Condlin, M. L., Urso, M. L., van den Berg, R. M., van Helden, H. P. M., Montain, S. J., & Joosen, M. J. A. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5614 · Cited by 19
“Prostaglandins Leukot Essent Fatty Acids 2013; 89(2-3): 97-105.”
InfluentialFeng, G.-L., Feng, J., Zhang, S.-J., Tong, Y., Zhang, Q., Yang, X.-M., & Zhang, H.-P. (2018) · Brain Research · doi:10.1016/j.brainres.2018.05.044 · Cited by 14
Anderson, G., Peterson, T. C., Haar, C. V., Kantor, E., Farin, F., Bammler, T., MacDonald, J. W., & Hoane, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00129 · Cited by 14
“…of destructive enzymes, membrane disruption, neuronal death, thrombosis due to intravascular coagulation in small vessels, increased synaptic concentrations of excitatory amino acids, and activation of innate inflammatory responses (Wang et al., 2006; Jennings et al., 2008; McConeghy et al., 2012).”
BackgroundMethodInfluentialTaylor, M. D., & Krishnan, K. (2015) · CRC Press eBooks · doi:10.1201/b18386-29 · Cited by 13
Lenell, S., Nyholm, L., Lewén, A., & Enblad, P. (2015) · Acta Neurochirurgica · doi:10.1007/s00701-014-2329-9 · Cited by 13
Ischemic, Traumatic and Neurodegenerative Brain Inflammatory Changes
Dugue, R., & Barone, F. C. (2016) · Future Neurology · doi:10.2217/fnl.16.5 · Cited by 11
Labombarda, F., & Garcia-Ovejero, D. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.139456 · Cited by 11
“In TBI, like in SCI, several therapeutical approaches have been followed, including high dose methylprednisolone, but none of them has become a gold standard for acute care (Margulies et al., 2009; McConeghy et al., 2012).”
Traumatic brain injury heterogeneity affects cell death and autophagy
McDonald, B. Z., Tarudji, A. W., Zhang, H., Ryu, S., Eskridge, K. M., & Kievit, F. M. (2024) · Experimental Brain Research · doi:10.1007/s00221-024-06856-1 · Cited by 9
“Overall, this breadth amongst the clinical population, with respect to both injury and outcome, is one of the primary contributors to challenges facing clinical trials and preclinical translation (Doppenberg et al. 2004; Howard et al. 2017; McConeghy et al. 2012; Narayan et al. 2002; Stein 2015).”
Traumatic Brain Injury: An Update
Zakaria, E., & Joseph, B. (2017) · Surgical Research - Open Journal · doi:10.17140/sroj-4-e003 · Cited by 10
Negro‐Demontel, M. L., Saccardo, P., Giacomini, C., Yáñez‐Muñoz, R. J., Ferrer‐Miralles, N., Vázquez, E., Villaverde, A., & Peluffo, H. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.47 · Cited by 9
Traumatic Brain Injury and Diet
Greco, T., & Prins, M. L. (2013) · Journal of Child Neurology · doi:10.1177/0883073813487594 · Cited by 9
“In human trials, it has been less clear if magnesium has definitive neuroprotective effects.(54) Branched-chain amino acids have also been shown to be decreased following injury and are precursors of glutamate and g-aminobutyric acid synthesis, which are involved in synaptic function and cellular metabolism and are cr…”
BackgroundProtective effects of batroxobin on a nigrostriatal pathway injury in mice.
Li, D., Tong, L., Kawano, H., Liu, N., Liu, L., & Li, H.-P. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.09.014 · Cited by 9
Specific intensive care management of patients with traumatic brain injury: Present and future
Chowdhury, T., Kowalski, S., Arabi, Y., & Dash, H. (2014) · Saudi Journal of Anaesthesia · doi:10.4103/1658-354x.130746 · Cited by 9
“Most of the therapies are being developed toward the minimization of secondary brain injuries and includes hyperbaric oxygen therapy (HBOT), neuroprotective agents and gene/stem cell therapy.[50-56]”
BackgroundGong, Q.-Y., Wang, W., Cai, L., Yao, J., Yang, D., Yuan, F., Tian, H., Ding, J., Chen, H., & Xu, Z. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101902 · Cited by 10
Effective treatment of traumatic brain injury by injection of a selenium-containing ointment
Hu, H., Gao, H., Wang, K., Jin, Z., Zheng, W., 王俏镟, Yang, Y., Yu, C., Yu, C., & Gao, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.08.051 · Cited by 8
Norins, L. C. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.04.019 · Cited by 11
Toklu, H. Z., Sakarya, Y., & Tümer, N. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6952-4_16 · Cited by 8
Steroid profiling in brain and plasma of adult zebra finches following traumatic brain injury
Gray, S. L., Soma, K. K., & Duncan, K. A. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13151 · Cited by 5
“As there is no approved medical therapy for TBI, steroid hormones have been studied extensively as potential targets for new therapies.(9,10) The main steroid studied in this context is 17β-estradiol (E2).”
BackgroundEffect of Polyarginine Peptide R18D Following a Traumatic Brain Injury in Sprague-Dawley Rats
Chiu, L.-S., Anderton, R., Clark, V., Cross, J., Knuckey, N., & Meloni, B. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100584 · Cited by 6
Jiang, J.-P., Niu, X., Dai, C., Ma, K., Xu, H., Cheng, S.-X., Zhang, Z.-W., Duan, F., Zhu, X., Wang, Y., et al. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250578 · Cited by 6
“TBI is a serious public health problem worldwide that causes death and disability, such as cognitive deficits, dysphasia, and hemiplegia (Royo et al., 2003; McConeghy et al., 2012; Shi et al., 2012).”
BackgroundDelSignore, L. A., & Tasker, R. C. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1380520 · Cited by 6
“Given the high morbidity and degree of functional neurological disability in survivors of severe TBI, emerging therapies have focused on known sequelae of TBI that may contribute to improved functional outcomes, including derangements encountered in the neuroendocrine system and autonomic nervous systems [49,50].”
BackgroundZhang, Z., Gao, X., Tian, Z., Yang, E., Huang, Y., Liu, D., Dai, S., Zhang, H., Bao, M., Jiang, X., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01916-5 · Cited by 6
“…animal experiments have con fi rmed that pharmacological antagonists of GluRs, including N-methyl-D-aspartate receptors (NMDARs) and metabotropic GluRs (mGluRs), can signi fi cantly reduce excitotoxic injury after TBI, these drugs did not achieve optimal results in a series of clinical trials [5, 6].”
BackgroundWalter, J., Mende, J., Hutagalung, S., Grutza, M., Younsi, A., Zheng, G., Unterberg, A., & Zweckberger, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265448 · Cited by 5
The Anesthesiologist’s Role in Treating Abusive Head Trauma
Lee, J. K., Brady, K., & Deutsch, N. (2016) · Anesthesia and Analgesia · doi:10.1213/ane.0000000000001298 · Cited by 5
Chapter 5 – Traumatic Brain Injury
Chakraborty, S., Skolnick, B., Alves, W., Marshall, L., & Narayan, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-804064-5.00005-9 · Cited by 5
Shen, S., Zhang, M., Ma, M., Rasam, S., Poulsen, D., & Qu, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052246 · Cited by 4
“Because of the highly complex and heterogeneous nature of TBI [3], a comprehensive and in-depth systems biology approach is warranted to understand the molecular mechanisms underlying TBI-induced neuropathy and to better facilitate the clinical management of TBI patients and the development of promising therapeutic dr…”
BackgroundÜçal, M., Maurer, C., Etschmaier, V., Hamberger, D., Grünbacher, G., Tögl, L., Roosen, M. J., Molčányi, M., Vorholt, D., Hatay, F. F., et al. (2021) · Journal of Neurotrauma · doi:10.1089/neu.2020.7017 · Cited by 4
Chen, S.-L., Deng, Y.-Y., Wang, Q.-S., Han, Y.-L., Jiang, W.-Q., Fang, M., Hu, B., Wu, Z.-X., Huang, L.-Q., & Zeng, H.-K. (2017) · Medicine · doi:10.1097/md.0000000000005786 · Cited by 4
Qin, D., Du, W., Sha, S., Parkinson, A., & Glasgow, N. (2019) · International Journal of Mental Health Nursing · doi:10.1111/inm.12627 · Cited by 3
“…conventional pharmaceutical interventions have not been found to achieve permanent successful results for these patients with their complex physical and psychosocial needs (Gallagher & Herrmann 2015; Leskovec et al. 2008; McConeghy et al. 2012; Mercken et al. 2011; Vandenberghe et al. 2016).”
BackgroundAmouzeshi, A., & Pourbagher-Shahri, A. (2019) · Journal of Surgery and Trauma · doi:10.32592/jsurgery.2019.7.1.101 · Cited by 3
Sortilin is dispensable for secondary injury processes following traumatic brain injury in mice
Lasarzik, I., Gölz, C., Bobkiewiecz, W., Somnuke, P., Sebastiani, A., Thal, S. C., & Schäfer, M. K. E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35198 · Cited by 3
“Consequently, therapeutic options are limited to surgical interventions and supportive therapies [7 – 9].”
BackgroundMicronutrients in brain function, and traumatic brain injury.
Lukaski, H., & Hardy, G. (2013) · Current opinion in clinical nutrition and metabolic care · doi:10.1097/mco.0b013e328365a2ce · Cited by 2
“Antioxidants can reduce mitochondrial oxidative damage, systemic inflammation and organ dysfunction leading to improved mitochondrial respiration, reduced oxidative stress, decreased plasma interleukin-6 (IL-6) and liver enzyme levels in sepsis [8].”
BackgroundTargeting Microglia: A New Avenue for Anesthesia Neuroprotection after Brain Injury?
Vutskits, L., & Sall, J. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002272 · Cited by 1
Kobeissy, F. H., & Stevens, S. M. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6952-4 · Cited by 1
Stem Cells for Neurovascular Repair in CNS Trauma
Pabón, M., Dailey, T., Tajiri, N., Shinozuka, K., Ishikawa, H., Acosta, S., Kaneko, Y., & Borlongan, C. (2014) · doi:10.1007/978-1-4614-8690-9_11 · Cited by 1
“Recent clinical trials have targeted the acute phase of injury using neuroprotective drugs [14–18] and have also tested prophylactic treatments such as hypothermia to lessen TBI injury [19].”
BackgroundMolecular Biomarkers in Traumatic Brain Injury: Diagnostic, Prognostic, and Therapeutic Perspective
Setiasari, F. J., Putri, S. M., Puspasari, B. S., & Ilham, M. F. (2025) · JURNAL BIOLOGI TROPIS · doi:10.29303/jbt.v25i4.10237
“Pendekatan ini diharapkan dapat meningkatkan validitas dan standarisasi biomarker sehingga lebih siap diterapkan dalam praktik klinis (McConeghy et al ., 2012; Zetterberg & Blennow, 2016).”
Li, J., Pan, Y., Chen, J., Wang, Y., Zhou, H., Huang, X., & Liao, S. (2021) · Ibrain · doi:10.1002/j.2769-2795.2021.tb00071.x
Coca Bitters-Numbing the Fatigue Rather Than the Pain.
Sall, J. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002358
Translational obstacles with off-label drug use in acute traumatic brain injury
Mirzaei, S., Reinig, A., & Berlau, D. (2017) · Future Neurology · doi:10.2217/fnl-2016-0032
Should reperfusion be revisited?
Morrissette, K. M., & Paradis, N. A. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.02.070
Alves, J. L., & Pinto, A. (2013) · Brazilian Neurosurgery · doi:10.1055/s-0038-1625993
Ciszek, B., Zygańska, E., Skadorwa, T., & Eibl, M. (2012) · doi:10.1016/s2084-5308(12)70072-2
Brain Injury: Refinement and Restoration—The Light Is Coming On
ZAFONTE, R. D. (2012) · PM&R · doi:10.1016/j.pmrj.2012.07.008
“Although numerous clinical trials for neuroprotection have failed to show efficacy, a bright light exists in the refinement and neurorestorative arenas for the near future [3].”
BackgroundDilimulati, D., Zhang, L., Duan, Y.-R., & Jia, F. (2022) · BIO Integration · doi:10.15212/bioi-2022-0001
Role of nutraceuticals in the management of severe traumatic brain injury
Teegala, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820593-8.00005-7
Stocchetti, N., & Carbonara, M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190280253.003.0002
Dekompressive Kraniektomie auch günstig für die neurologische Erholung?
Walter, J., Unterberg, A., & Zweckberger, K. (2018) · Neurotransmitter · doi:10.1007/s15016-018-6261-8
RETRACTED CHAPTER: Brain Trauma and Nutritional Support
Wetsch, W., Böttiger, B., & Padosch, S. A. (2015) · Springer eBooks · doi:10.1007/978-1-4614-7836-2_72
RetractedBrain Trauma and Nutritional Support
Wetsch, W., Böttiger, B., & Padosch, S. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8503-2_72-1
Metadata
- Authors
- McConeghy, K. W., Hatton, J., Hughes, L., & Cook, A. M.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
- Corresponding author
- Cook, Aaron M.
- Venue
- CNS Drugs
- Published
- 2012-07
- Volume
- 26
- Issue
- 7
- Pages
- 613-636
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2006925820
- Cited by
- 158
- References
- 0
- Citations by year
- 2025: 4 · 2024: 8 · 2023: 3 · 2022: 10 · 2021: 8 · 2020: 10 · 2019: 11 · 2018: 16 · 2017: 20 · 2016: 17 · 2015: 18 · 2014: 17 · 2013: 13 · 2012: 3
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- traumatic brain injury, neuroprotection, secondary brain injury, intracranial pressure, cerebral perfusion, calcium influx, mitochondrial dysfunction, redox homeostasis, blood flow, cytoskeleton, magnesium, progesterone, cyclosporine, biomarkers, clinical trial design
- MeSH terms
- Animals, Brain Injuries, Clinical Trials as Topic, Humans, Prognosis, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review